This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

DICE Therapeutics Temettü

Temettü kriter kontrolleri 0/6

DICE Therapeutics does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$2.18
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

May 14

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Oct 11

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

Sep 11

DICE Therapeutics GAAP EPS of -$0.58

Aug 11

DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs

Jul 18

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if DICE's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if DICE's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

DICE Therapeutics Piyasaya Karşı Temettü Getirisi

DICE temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (DICE)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Pharmaceuticals)	2.2%
Analist tahmini (DICE) (3 yıla kadar)	0%

Önemli Temettü: Unable to evaluate DICE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate DICE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as DICE has not reported any payouts.

This company has been acquired

DICE Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders.

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion.

New minor risk - Share price stability

Price target decreased by 13% to US$56.30

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

Independent Director recently sold US$291k worth of stock

DICE Therapeutics, Inc. Announces Board Changes

High number of new directors

DICE Therapeutics, Inc. Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

DICE Therapeutics GAAP EPS of -$0.58

DICE Therapeutics, Inc. Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806

DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs

DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 2000 Growth Index

High number of new directors

High number of new directors

DICE Therapeutics, Inc. Expands Management Team and Board of Directors

Third quarter 2021 earnings released: US$2.30 loss per share

DICE Therapeutics, Inc. has completed an IPO in the amount of $204 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin